MDNA Life Sciences Agrees Licensing Deal with Aspire Pharma Ltd for the Mitomic® Prostate Test in the UK

MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has agreed a licensing deal with Aspire Pharma Ltd. (Aspire) in the UK for the Mitomic® Prostate Test (MPT™). On the heels of recent news that MDNA’s CE marked MPT™ Real-Time PCR kit is now commercially available, this is the first international partner to be announced by MDNA and is the start of the global roll-out of MPT™through a growing network of distribution partners.

MDNA Life Sciences and University of Oxford to collaborate to develop a Mitochondrial Biomarker blood-based diagnostic for endometriosis

MDNA Life Sciences has entered into a collaboration agreement with the University of Oxford to further the development and validation of MDNA’s non-invasive blood-based test for endometriosis.